MOESM1 of Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study) Hiroki Nakajima Sadanori Okada Takako Mohri Eiichiro Kanda Naoyuki Inaba Yoko Hirasawa Hiroaki Seino Hisamoto Kuroda Toru Hiyoshi Tetsuji Niiya Hitoshi Ishii 10.6084/m9.figshare.5938009.v1 https://springernature.figshare.com/articles/journal_contribution/MOESM1_of_Dapagliflozin_improves_treatment_satisfaction_in_overweight_patients_with_type_2_diabetes_mellitus_a_patient_reported_outcome_study_PRO_study_/5938009 Additional file 1. List of the 29 medical institutions participating in the study. The data on this file include the names of the 29 participating medical institutions in this multi-center study. 2018-03-01 05:00:00 Type 2 diabetes mellitus Oral hypoglycemic agent Sodium glucose cotransporters 2 inhibitors SGLT2 inhibitors Dapagliflozin Treatment satisfaction Oral Hypoglycemic Agent-Questionnaire Body weight Patient reported outcome Quality of life